AlphAIAlphAI — Financial news for AI agents
gurufocus.comSEP 232 min read$GOSS

Gossamer Bio (GOSS) Files NDA for Seralutinib Amidst Challenging

Gossamer Bio (GOSS) filed an NDA for seralutinib, its treatment for pulmonary arterial hypertension. The submission is based on clinical data from the PROSERA and TORREY studies, though the PROSERA trial did not meet its primary endpoint. GOSS trades at a P/S ratio of 0.62, below its historical median and industry averages, reflecting market skepticism. The company has a GF Score of 22/100, indicating significant financial and operational challenges.

Original reporting
gurufocus.com
Published Sep 23, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 3:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$GOSS
Neutral
medium confidence
Mentioned
$GOSS
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$GOSSNeutralMed
01

Why it matters

The NDA filing is a pivotal regulatory milestone; market reaction will hinge on FDA feedback.

02

Market read

First‑time NDA filing for a rare‑disease therapy; creates a tradeable event for GOSS.

03

What to watch

Potential for partnership or licensing deals that could de‑risk the program.

Relevance 8/10Novelty 9/10Timing: today

Background

Gossamer Bio is a small‑cap clinical‑stage biotech focusing on pulmonary arterial hypertension.

Company-level read

Ticker impact

$GOSSNeutralMedium confidence
Context

Gossamer Bio filed an FDA New Drug Application for seralutinib, its first NDA submission.

Expected impact

Possible short-term rally on approval news; long-term risk if FDA rejects due to trial results.

Evidence & confidence

Regulatory filing is material, yet clinical data are mixed, leading to uncertain market reaction.

Market effects

Sector

Highlights challenges in the PAH biotech niche and may affect peer valuations.

Regional

Primarily impacts US biotech investors; limited broader market effect.

Global

Limited to biotech sector, no major macro implications.

Counterpoint

What could challenge this read

If the FDA grants approval despite missed endpoint, the stock could see a sharp upside.

Key entities

  • company
    Gossamer Bio Inc.

    Biopharma developing seralutinib for PAH.

  • regulator
    FDA

    U.S. agency reviewing the NDA.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 13
$GOSSMed

Chardan initiates Gossamer Bio stock with buy on PAH therapy potential

Chardan initiated coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and $160 price target, citing potential FDA approval of seralutinib for PAH therapy. The stock is near its 52-week low at $9.28. The company has a market cap of $56.76M and faces an NDA decision in Q4 2026. Chardan estimates $1.3B in 2035 revenue if approved. Gossamer recently submitted an NDA for seralutinib, supported by clinical trial data. Leerink and H.C. Wainwright also issued positive ratings.

investing.com2 min
SEP 23
$GOSSHighAI 8/10

Gossamer Bio stock rises on FDA filing for PAH drug

Gossamer Bio (GOSS) shares rose 3.7% after-hours after submitting a New Drug Application for seralutinib, a treatment for pulmonary arterial hypertension, to the FDA. The submission is backed by Phase 3 and Phase 2 study data. The FDA will decide whether to accept the application for review later this year.

investing.com2 min
SEP 23
$GOSSMedAI 8/10

Gossamer Bio, Inc. announced that it submitted a New Drug Application to the U.S. Food and Drug Administration in September 2026 for seralutinib for the…

Gossamer Bio, Inc. (GOSS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 23, 2026, Gossamer Bio, Inc. (the “Company”) announced that it submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in September 2026 for seralutinib for the treatment of pulmonary arterial hypertension (“P

SEC EDGAR 8-K2 min
AUG 27
$GOSSMedAI 8/10

Gossamer (GOSS) Announced Up to $250M of Financing, but Only $25M is Expected Upfront. Is the Runway Secure?

Gossamer Bio (GOSS) announced a private placement with up to $250M in gross proceeds, but only $25M is expected upfront. The remaining funds are contingent on regulatory milestones for seralutinib, a drug for pulmonary arterial hypertension. The company ended June with $57M in cash, expecting the initial $25M to improve near-term liquidity but not fully secure its runway.

insidermonkey.com3 min